Is alectinib the new first line therapy in ALK-rearranged advanced non-small cell lung cancer?

被引：1
|
作者：
van der Wekken, Anthonie J. [1 ]
Kok, Klaas [2 ,3 ]
Groen, Harry J. M. [1 ]
机构：
[1] Univ Groningen, Dept Pulm Dis, Groningen, Netherlands
[2] Univ Groningen, Dept Genet, Groningen, Netherlands
[3] Univ Med Ctr Groningen, Hanzepl 1, NL-9713 GZ Groningen, Netherlands
来源：
JOURNAL OF THORACIC DISEASE | 2018年 / 10卷
关键词：
CRIZOTINIB; RESISTANCE; INHIBITOR;
D O I：
10.21037/jtd.2018.06.45
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
引用
收藏
页码：S2130 / S2132
页数：3
相关论文
共 50 条
  • [21] Overcoming crizotinib resistance in ALK-rearranged non-small cell lung cancer
    Qi, Xiaolong
    Ma, Wang
    Li, Sen
    Zhou, Caicun
    LUNG CANCER, 2014, 85 (02) : 335 - 336
  • [22] New Strategies for Treatment of ALK-Rearranged Non-Small Cell Lung Cancers
    Sasaki, Takaaki
    Jaenne, Pasi A.
    CLINICAL CANCER RESEARCH, 2011, 17 (23) : 7213 - 7218
  • [23] ALK-rearranged Non-Small Cell Lung Cancer Cystic Brain Metastases
    Lakhani, Dhairya A.
    Deng, Francis
    RADIOLOGY, 2024, 313 (01)
  • [24] Updated Survival Data in Advanced ALK-rearranged Non-small Cell Lung Cancer Treated with Alectinib and Bevacizumab in the ALEK-B Study
    Arrieta, O.
    Lara-Mejia, L.
    Cabrera-Miranda, L.
    Heredia, D.
    Ramos-Ramirez, M.
    Caballe, E.
    Davila-Dupont, D.
    Cardona, A. F. F.
    Cruz-Rico, G.
    Remon, J.
    Rosell, R.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S355 - S356
  • [25] ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
    Mota, Ines
    Patrucco, Enrico
    Mastini, Cristina
    Mahadevan, Navin R.
    Thai, Tran C.
    Bergaggio, Elisa
    Cheong, Taek-Chin
    Leonardi, Giulia
    Karaca-Atabay, Elif
    Campisi, Marco
    Poggio, Teresa
    Menotti, Matteo
    Ambrogio, Chiara
    Longo, Dario L.
    Klaeger, Susan
    Keshishian, Hasmik
    Sztupinszki, Zsofia M.
    Szallasi, Zoltan
    Keskin, Derin B.
    Duke-Cohan, Jonathan S.
    Reinhold, Bruce
    Carr, Steven A.
    Wu, Catherine J.
    Moynihan, Kelly D.
    Irvine, Darrell J.
    Barbie, David A.
    Reinherz, Ellis L.
    Voena, Claudia
    Awad, Mark M.
    Blasco, Rafael B.
    Chiarle, Roberto
    NATURE CANCER, 2023, 4 (07) : 1016 - +
  • [26] ALK peptide vaccination restores the immunogenicity of ALK-rearranged non-small cell lung cancer
    Ines Mota
    Enrico Patrucco
    Cristina Mastini
    Navin R. Mahadevan
    Tran C. Thai
    Elisa Bergaggio
    Taek-Chin Cheong
    Giulia Leonardi
    Elif Karaca-Atabay
    Marco Campisi
    Teresa Poggio
    Matteo Menotti
    Chiara Ambrogio
    Dario L. Longo
    Susan Klaeger
    Hasmik Keshishian
    Zsófia M. Sztupinszki
    Zoltan Szallasi
    Derin B. Keskin
    Jonathan S. Duke-Cohan
    Bruce Reinhold
    Steven A. Carr
    Catherine J. Wu
    Kelly D. Moynihan
    Darrell J. Irvine
    David A. Barbie
    Ellis L. Reinherz
    Claudia Voena
    Mark M. Awad
    Rafael B. Blasco
    Roberto Chiarle
    Nature Cancer, 2023, 4 : 1016 - 1035
  • [27] Treatment modalities for advanced ALK-rearranged non-small-cell lung cancer
    Sullivan, Ivana
    Planchard, David
    FUTURE ONCOLOGY, 2016, 12 (07) : 945 - 961
  • [28] Ceritinib as First-Line Therapy in Patients with ALK-Rearranged Non-Small Cell Lung Cancer: ASCEND-1 Subgroup Analysis
    Tan, Daniel Shao-Weng
    Felip, Enriqueta
    Chow, Laura Qm
    Sharma, Sunil
    Urban, Patrick
    Malet, Isabelle
    Sutradhar, Santosh
    Li, Siyu
    Shaw, Alice
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1169 - S1170
  • [29] Alectinib as first-line therapy for ALK-rearranged NSCLC: a no-brainer?
    Thai, A. A.
    Solomon, B. J.
    ANNALS OF ONCOLOGY, 2018, 29 (11) : 2160 - 2162
  • [30] Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer
    Califano, Raffaele
    Greystoke, Alastair
    Lal, Rohit
    Thompson, Joyce
    Popat, Sanjay
    LUNG CANCER, 2017, 111 : 51 - 58
12345